PARP Inhibitor–based Combinations for the Management of Patients with Metastatic Castration-resistant Prostate Cancer: What Are the Data Telling Us?

PARP Inhibitor–based Combinations for the Management of Patients with Metastatic Castration-resistant Prostate Cancer: What Are the Data Telling Us? is organized by Med Learning Group.

Release Date: May 31, 2022
Expiration Date: May 31, 2023

Program Overview:
This enduring activity has been designed for HCPs treating metastatic castration-resistant prostate cancer (mCRPC) to improve: knowledge of the mechanisms of action of PARP inhibitor-based combinations for the treatment of patients with mCRPC with or without DNA damage response (DDR) alterations; awareness of new clinical data on the efficacy, safety, and tolerability of emerging PARP inhibitor-based combinations with different mechanisms of action for the treatment of patients with mCRPC; and their ability to develop individualized management plans for patients with mCRPC with or without DDR alterations that include PARP inhibitor-based combinations if appropriate.

Learning Objectives:
Upon the completion of this program, attendees should be able to:
• Support the biological and clinical rationale for the use of PARP inhibitor-based combinations for the treatment of mCRPC with or without DDR alterations
• Interpret evidence from clinical trials assessing the efficacy, safety, and tolerability of emerging PARP inhibitor-based combinations with different mechanisms of  action for the treatment of mCRPC
• Develop management plans that are individualized for patients with mCRPC with or without DDR alterations that include PARP inhibitor-based combinations if appropriate